Results from dosing regimen in PROTECT VIII study

This site is intended for US residents.

REGISTER

SELECTED IMPORTANT SAFETY INFORMATION: Jivi is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, polyethylene glycol (PEG), mouse or hamster proteins, or other constituents of the product. CONTINUE READING BELOW

Total ABR in all patients on every-7-day dosing arm (n=43); median (Q1;Q3) ABR for total bleeds of 3.9 (0.0;6.5) and a mean (±SD) of 6.43 (±10.04)^2,3

Total ABR in patients who completed every-7-day dosing treatment (n=32); median (Q1;Q3) ABR of 1.0 (0.0;4.3) and a mean (±SD) of 2.67 (±3.82)^2,3

Spontaneous ABR in all patients on every-7-day arm (n=43); median (Q1;Q3) of 1.9 (0.0,6.3) and mean (±SD) of 5.42 (±9.79)^2,3

Spontaneous ABR in patients who completed every-7-day dosing treatment (n=32); median (Q1;Q3) of 0.0 (0.0;2.1) and mean (±SD) of 1.65 (±2.89)^2,3

Total ABR in all patients on every-7-day dosing arm in the extension study (n=23); median (Q1;Q3) ABR for total bleeds of 0.7 (0;1.6) and a mean (±SD) of 2.0 (±4.1)⁴

Spontaneous ABR in all patients on every-7-day dosing arm in the extension study (n=23); median (Q1;Q3) ABR for spontaneous bleeds of 0.2 (0.0;0.8) and a mean (±SD) of 1.5 (±4.0)⁴

In the PROTECT VIII main study

Effective bleed protection with Jivi®1

Treatment success in the every-7-day arm was not established

In the PROTECT VIII long-term extension study

ABRs assessed with Jivi®4

Treatment success in the every-7-day was not established

Effective bleed protection with Jivi^®1

ABRs assessed with Jivi^®4